Peptide LibraryPramlintide dosage in published studies and labels
These are the doses used for Pramlintide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Pramlintide has an FDA-approved human dosage as an add-on to mealtime insulin. SymlinPen in type 2 diabetes starts at 60 mcg under the skin just before each major meal and goes to 120 mcg; in type 1 diabetes it starts at 15 mcg and goes up in 15 mcg steps to 30, 45 or 60 mcg. Mealtime insulin is cut by 50% when it is started.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 15–120 mcg before each major meal, depending on diabetes type |
| Route | Subcutaneous |
| Frequency | Immediately before each major meal |
| Duration studied | Continuous |
| Titration | Step up only after at least 3 days without clinically significant nausea. Type 2: 60 mcg, then 120 mcg. Type 1: 15 mcg, then 30, 45 or 60 mcg. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — SymlinPen, type 2 diabetesFDA-approved label · FDA prescribing information | Adults with type 2 diabetes using mealtime insulin who are not at glucose goal | Start 60 mcg; increase to 120 mcg; back to 60 mcg if nausea persists | Subcutaneous, abdomen or thigh | Immediately before each major meal | Continuous | Glycemic control alongside insulin | SYMLINPEN (pramlintide acetate) injection — FDA prescribing information, DailyMed |
| FDA label — SymlinPen, type 1 diabetesFDA-approved label · FDA prescribing information | Adults with type 1 diabetes using mealtime insulin who are not at glucose goal | Start 15 mcg; increase in 15 mcg steps to 30, 45 or 60 mcg; back to 30 mcg if nausea persists | Subcutaneous, abdomen or thigh | Immediately before each major meal | Continuous | Glycemic control alongside insulin | SYMLINPEN (pramlintide acetate) injection — FDA prescribing information, DailyMed |
Where sources disagree
- The SymlinPen label carries a boxed warning: used with insulin, pramlintide raises the risk of severe hypoglycemia, especially in type 1 diabetes, within 3 hours of an injection. The label requires a 50% cut in mealtime insulin when pramlintide is started.
- Type 1 and type 2 doses differ about fourfold; a figure from one does not apply to the other.